AzTrials
AzTrials

Parkinson DiseasePhase 3NCT03877510

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

A Phase 3 study testing IPX203 in people with Parkinson Disease, run by Impax Laboratories, LLC at 98 sites in 8 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Parkinson Disease
What is being tested?
IPX203
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
419 participants
Where
98 sitesin 8 countries
Study dates
3 Apr 2019to 21 Mar 2022
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Successfully completed Study IPX203-B16-02
  • Able to provide written informed consent prior to the conduct of any study-specific procedures.
  • Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit (Visit 1).
  • Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study.

Who cannot join

  • Intends to use any doses of Rytary® or Duopa™ during this study.
  • Plans to use an investigational treatment other than IPX203 during the course of this study.
  • Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.
  • Participants who, in the opinion of the clinical investigator, should not participate in the study.

Trial locations and contacts

98 sites in 8 countries.

98 sites in 8 countries

United States50 sites
  • Albany Medical College (139)

    Albany, New York, 12208

  • Emory Brain Health Center (110)

    Atlanta, Georgia, 30329

  • JEM Research Institute (136)

    Atlantis, Florida, 33462

  • University of Colorado Hospital Anschutz Outpatient Pavilion (120)

    Aurora, Colorado, 80045

  • Visionary Investigators Network (168)

    Aventura, Florida, 33180

  • UHealth at Boca Raton (152)

    Boca Raton, Florida, 33431

  • Parkinson's Disease and Movement Disorders Center of Boca Raton (121)

    Boca Raton, Florida, 33486

  • Northwestern Medical Group Neurology Clinic (145)

    Chicago, Illinois, 60611

  • Ucgni (133)

    Cincinnati, Ohio, 45219

  • University Hospitals Cleveland Medical Center (123)

    Cleveland, Ohio, 44106

  • Cleveland Clinic(144)

    Cleveland, Ohio, 44195

  • Neurology Consultants of Dallas, PA (108)

    Dallas, Texas, 75251

  • University of Texas Southwestern Medical Center (143)

    Dallas, Texas, 75390-9184

  • NeuroStudies.net, LLC (155)

    Decatur, Georgia, 30033

  • Rocky Mountain Movement Disorders (116)

    Englewood, Colorado, 80113

  • Inova Neurology- Fairfax (147)

    Fairfax, Virginia, 17601

  • Quest Research Institute (103)

    Farmington Hills, Michigan, 48334

  • VCU Health- Neuroscience Orthopaedic and Wellness Center(124)

    Henrico, Virginia, 23233

  • Infinity Clinical Research LLC (104)

    Hollywood, Florida, 33024

  • Houston Methodist Neurological Institute/Movement Disorders Clinic (135)

    Houston, Texas, 77030

  • Indiana University Health Neuroscience Center(164)

    Indianapolis, Indiana, 46202

  • University of Florida Health Science Center (129)

    Jacksonville, Florida, 32209

  • University of Kansas Medical Center (118)

    Kansas City, Kansas, 66160

  • Booth Gardner Parkinson's Care Center (112)

    Kirkland, Washington, 98034

  • Roseman Medical Research Institute / Roseman Medical Group (154)

    Las Vegas, Nevada, 17601

  • Cleveland Clinic Lou Ruvo Center for Brain Health (142)

    Las Vegas, Nevada, 89106

  • Clinical Trials, Inc (113)

    Little Rock, Arkansas, 72205

  • University of Arkansas for Medical Sciences (117)

    Little Rock, Arkansas, 72205

  • Keek School of Medicine of USC/ University of Southern California (106)

    Los Angeles, California, 90033

  • Neurology Associates, P.A. (125)

    Maitland, Florida, 32751

  • University of Miami (149)

    Miami, Florida, 33136

  • Medical Professional Clinical Research Center, Inc. (163)

    Miami, Florida, 33165

  • The Vanderbilt Clinic (158)

    Nashville, Tennessee, 37232

  • ChristianaCare Neurology Specialists (153)

    Newark, Delaware, 19713

  • Hoag Memorial Hospital Presbyterian (134)

    Newport Beach, California, 92663

  • SC3 Research-Pasadena (148)

    Pasadena, California, 91105

  • Xenoscience, Inc (102)

    Phoenix, Arizona, 85004

  • St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (156)

    Phoenix, Arizona, 85013

  • Parkinson's Disease Treatment Center of Southwest Florida (131)

    Port Charlotte, Florida, 33980

  • SC3 Research-Reseda (146)

    Reseda, California, 91335

  • Inland Northwest Research (119)

    Spokane, Washington, 99202

  • Washington University (109)

    St Louis, Missouri, 63110

  • Infinity Clinical Research, LLC (105)

    Sunrise, Florida, 33351

  • University of South Florida (114)

    Tampa, Florida, 33615

  • University of Toledo, Gardner-McMaster Parkinson Center (122)

    Toledo, Ohio, 43614

  • The Movement Disorder Clinic of Oklahoma (115)

    Tulsa, Oklahoma, 74136

  • Henry Ford West Bloomfield Hospital(100)

    West Bloomfield, Michigan, 48322

  • Premiere Research Institute at Palm Beach Neurology (174)

    West Palm Beach, Florida, 33407

  • Central DuPage Hospital (151)

    Winfield, Illinois, 60190

  • Charter Research (166)

    Winter Park, Florida, 32792

Other trials in United States

Spain14 sites
  • Hospital Universitario Quiron Dexeus (501)

    Barcelona, 08028

  • Germanes Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516)

    Barcelona, 08035

  • Hospital Universitario Vall d'Hebron (505)

    Barcelona, 08035

  • Hospital de Ia Santa Creu i Sant Pau (502)

    Barcelona, 08041

  • Policlinica Gipuzkoa, S.A (511)

    Donostia / San Sebastian, Gipuzkoa, 20014

  • Hospital General Universitario de Elche (509)

    Elche, Alicante, 03203

  • Hospital Universitario de Ia Princesa (508)

    Madrid, 28006

  • Hospital Universitario Ramon y Cajal (500)

    Madrid, 28034

  • Hospital Universitario Infanta Sofia(513)

    Madrid, 28703

  • Clinica Universidad de Navarra (512)

    Pamplona, Navarre, 31008

  • Hospital Universitari General de Catalunya (504)

    Sant Cugat del Vallès, Barcelona, 08195

  • Hospital Universitario Virgen del Rocio (503)

    Seville, 41013

  • Hospital Universitari Mutua Terrassa (506)

    Terrassa, Barcelona, 08222

  • Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell (515)

    Valencia, 46026

Other trials in Spain

Italy8 sites
  • Centro Ricerca Parkinson San Raffaele Cassino (601)

    Cassino, Frosinone, 03043

  • Department "G. F. Ingrassia" section of neuroscience - Policlinico "Vittorio Emanuele" (608)

    Catania, Sicily, 95123

  • Università G. D'annunzio CeSi Met (604)

    Chieti, Italy/Chieti/Abbruzzo, 66100

  • Fondazione I st ituto Neurologico Nazionale "C. Mondino" (606)

    Pavia, Italy/Pavia/Lombardia, 27100

  • Azienda Ospedaliero-Universitaria Pisana (602)

    Pisa, Italy/Pisa/Toscana, 56126

  • IRCCS San Raffaele Pi sana (600)

    Roma, Italy/Roma/Lazio, 00163

  • Department of neuroscience, mental health and sensory system (NeSMOS), "Sapienza" University (603)

    Roma, Italy/Roma/Lazio, 00189

  • University of Rome Tor Vergata/Hospital Tor Vergata (605)

    Rome, Lazio, 00133

Other trials in Italy

Poland7 sites
  • Centrum Medyczne Neuromed (803)

    Bydgoszcz, 85163

  • Centrum Medyczne Linden (805)

    Krakow, 30721

  • Krakowska Akademia Neurologii Sp. Zo.o.(802)

    Krakow, 31-505

  • NZOZ Neuromed M. i M. Nastaj Sp.p. (800)

    Lublin, 20-064

  • NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801)

    Poznan, 61853

  • Neuro-Care Sp. z o.o. sp. k. (804)

    Siemianowice Śląskie, 41100

  • Centrum Medycme NeuroProtect (806)

    Warsaw, 01-684

Other trials in Poland

Czechia6 sites
  • Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704)

    Brno, 65691

  • NEUROHK. s.r.o. (701)

    Choceň, 56501

  • Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702)

    Pardubice, 53203

  • CLINTRIAL s.r.o. (703)

    Prague, 10000

  • AXON Clinical. s.r.o. (700)

    Prague, 15000

  • Neurologicka ordinace FORBELI s.r.o. (706)

    Prague, 16000

Other trials in Czechia

Germany6 sites
  • Kliniken Beelitz GmbH, neurologisches Fachkrankenhaus fur Bewegungsstorungen/Parkinson (300)

    Beelitz-Heilstätten, Beelitz, 14547

  • Dr. med. Reinhardt Ehret Neuroloqie Berlin Schlobstr. 29 (309)

    Berlin, 12163

  • St. Josef-Hospital, Universitatsklinik fur Neurologie Klinisches Forschungszentrum fur Neurodegeneration (301)

    Bochum, Gudrunstabe 56, 44791

  • Klinik Haag i. OB Geriatric Hospital Krankenhausstrabe 4 (305)

    Haag in Oberbayern, 83527

  • Klinikum rechts der lsar der Technischen Universitat Munchen Klinik und Poliklinik fur Neurologie (303)

    München, Ismaningerstrabe, 81675

  • Gemeinschaftspraxis Dr. med. J. Springub/W. Schwarz, Studienzentrum Nordwest (306)

    Westerstede, 26655

Other trials in Germany

France4 sites
  • CHU de Clermont-Ferrand-Hopital Gabriel Montpied (404)

    Clermont-Ferrand, 63003

  • CHU de Montpellier, Hopital Gui de Chauliac (405)

    Montpellier, 34295

  • Centre Hospitalier Universitaire de Nice (400)

    Nice, 06002

  • Centre d'lnvestigation Clinique 1436- CHU Purpan- Hopital Pierre Paul Riquet (403)

    Toulouse, 31059

Other trials in France

United Kingdom3 sites
  • Imperial College Healthcare NI-lS Trust (200)

    London, W68RF

  • Re:Cognition Health Ltd (202)

    London, WlG9JF

  • Re:Cognition Health Ltd (205)

    Plymouth, Devon, PL68BT

Other trials in United Kingdom

About this study

Official title: An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.

Read the detailed description

This is a 9-month, multicenter open-label safety extension study. Participants who have successfully completed Study NCT03670953 [A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in this open-label study.

Being tested
IPX203
Keywords
motor fluctuations, IPX203
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IPX203Drug

    IPX203 extended release capsules

Study groups in NCT03877510
Study groupRoleWhat they receive
Open Label IPX203ExperimentalAll participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety.
Receives: Drug: IPX203

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Treatment-Emergent Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study.

    Measured: From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])

Secondary outcomes (28)
  1. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  2. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).

    Measured: Baseline, Month 9/ET

  3. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  4. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 9/ET

  5. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  6. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 9/ET

  7. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  8. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 9/ET

  9. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  10. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 9/ET

  11. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  12. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.

    Measured: Baseline, Month 9/ET

  13. Patient Global Impression of Severity (PGI-S)

    The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  14. Change From Baseline in Patient Global Impression of Severity (PGI-S)

    The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

    Measured: Baseline, Month 9/ET

  15. Percentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5

    The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  16. Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

    Measured: Baseline, Month 3, Month 6, Month 9/ET

  17. Change From Baseline in Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

    Measured: Baseline, Month 9/ET

  18. Percentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5

    The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  19. 39-item Parkinson's Disease Questionnaire (PDQ-39): Total

    The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  20. Change From Baseline in PDQ-39: Total

    The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Month 9/ET

  21. Parkinson Anxiety Scale (PAS): Total

    The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  22. Change From Baseline in Parkinson Anxiety Scale (PAS): Total

    The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.

    Measured: Baseline, Month 9/ET

  23. Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total

    The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  24. Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total

    The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.

    Measured: Baseline, Month 9/ET

  25. Parkinson's Disease Sleep Scale-2 (PDSS-2) Total

    The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.

    Measured: Baseline, Month 3, Month 6, and Month 9/ET

  26. Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total

    The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.

    Measured: Baseline, Month 9/ET

  27. Treatment Satisfaction Assessment (TSA)

    The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.

    Measured: Month 3, Month 6 and Month 9/ET

  28. Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)

    The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.

    Measured: Month 3, Month 6, and Month 9/ET

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2019
  2. Study start3 Apr 2019
  3. Primary completion21 Mar 2022
  4. Study completion21 Mar 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
419 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03877510
Sponsor's protocol ID
IPX203-B16-03
Other IDs
2018-002234-21, 2018
Status last verified
Jun 2023
First submitted
12 Mar 2019
Last updated
13 Jul 2023
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing IPX203 in people with Parkinson Disease, run by Impax Laboratories, LLC at 98 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 98 sites in United States, Spain, Italy, Poland, Czechia and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Jun 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Treatment-Emergent Adverse Events (time frame: From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in